Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | PDE5A | O76074 | 1/20 | 0.45 |
| ▸ | KRAS | P01116 | 2/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18702370 | 0.81 | SPR (1.00) | SPRSMN1; SMN2RAB9AMAPTPDE5A | |
| SCHEMBL26158246 | 0.80 | SPR (0.67) | SPRSMN1; SMN2RAB9AMAPTPDE5A | |
| SCHEMBL26890923 | 0.80 | SPR (0.66) | SPRSMN1; SMN2RAB9AMAPTPDE5A | |
| SCHEMBL13789308 | 0.76 | SMN1; SMN2 (0.74) | SPRSMN1; SMN2RAB9AMAPTPDE5A | |
| SCHEMBL13789401 | 0.72 | SMN1; SMN2 (0.59) | SPRSMN1; SMN2RAB9AMAPTPDE5A | |
| SCHEMBL13789393 | 0.71 | SPR (0.55) | SPRSMN1; SMN2RAB9AMAPTPDE5A | |
| SCHEMBL2408228 | 0.70 | SMN1; SMN2 (0.60) | SPRSMN1; SMN2RAB9AMAPTPDE5A | |
| SCHEMBL18689604 | 0.70 | SPR (1.00) | SPR | |
| SCHEMBL20665473 | 0.70 | SPR (0.69) | SPRSMN1; SMN2RAB9AMAPT | |
| SCHEMBL13789304 | 0.70 | SMN1; SMN2 (0.56) | SPRSMN1; SMN2RAB9AMAPTPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963462-B2 | Sepiapterin reductase inhibitors | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2018-05-08 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | SPR 1/4885SMN1; SMN2 2655/4885RAB9A 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.